Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06894745 · ClinicalTrials.gov registry record · Phase 1
PET [89Zr]DFO-starPEG in Solid Tumors
A Phase 1 study of Solid Tumor and Solid Carcinoma, sponsored by Robert Flavell, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT06894745 is a Phase 1 study of Solid Tumor and Solid Carcinoma that is actively recruiting participants, run by Robert Flavell, MD, PhD. The registered enrollment target is 13 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06894745, a Phase 1 study of Solid Tumor and Solid Carcinoma, is actively recruiting participants, sponsored by Robert Flavell, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-human, pilot study of the novel PET-imaging radiotracer \[89Zr\]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before administration of EPR-based nanomedicines.
Conditions Studied
Interventions
- PROCEDURE Specimen Collection
- DRUG 89-zr-dfo-star polyethylene glycol (StarPEG)
- PROCEDURE Whole Body Positron Emission Tomography (PET)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2025-06-02 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06894745
The ClinicalTrials.gov registry entry for NCT06894745 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (94% lower). The listed sponsor is Robert Flavell, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Specimen Collection is the first listed.
NCT06894745 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06894745 about?
NCT06894745 is a clinical study titled "PET [89Zr]DFO-starPEG in Solid Tumors". This is a first-in-human, pilot study of the novel PET-imaging radiotracer \[89Zr\]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before ad...
What is the current status of trial NCT06894745?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2025-06-02. Estimated completion is 2027-12-31.
What conditions does trial NCT06894745 study?
This clinical trial studies the following conditions: Solid Tumor, Solid Carcinoma, Soft Tissue Lesion.
What interventions are being tested in trial NCT06894745?
The interventions under investigation include: Specimen Collection (PROCEDURE), 89-zr-dfo-star polyethylene glycol (StarPEG) (DRUG), Whole Body Positron Emission Tomography (PET) (PROCEDURE).
Who is sponsoring clinical trial NCT06894745?
This trial is sponsored by Robert Flavell, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06894745 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.